Dr. Thomas Crook joins the Cognitive Labs advisory board

Thomas Crook, Ph.D., has joined the Cognitive Labs advisory board, in one of two announcements we will be making today. We first got to know Tom during the process of rolling out the BrainSpeed product on behalf of the wellness company Natrol (since acquired by Plethico Holdings of Mumbai). He also is highly recommended by several individuals holding academic posts at Stanford. He might be considered the founder of diagnostic cognitive clinical assessment in the pharmaceutical realm, with an extensive knowledge of neuropsychological instruments. His consulting work also includes institutions such as NASA and the FDA

Here is his background:

Dr. Thomas Crook is a worldwide expert on cognition and diagnostic cognitive instrumentation with 200 credited scientific papers, nine books, and 300 invited lectures. (See the Tom Crook section on Google Scholar) He has over thirty years experience in research related to the diagnosis, assessment, and treatment of adult-onset cognitive disorders. His background includes fourteen years at the NIH's NIMH division (National Institute of Mental Health) where he served as Chief of the Institute's Geriatric Psychopharmacology Program. He has appeared on Good Morning America, The Today Show, CBS This Morning, 20/20, CBS, NBC and CNN Evening News, CNBC Equal Time, and Prime Time Live, as well as Newsweek, Time, U.S. News and World Report, Forbes, Fortune, Esquire, Vogue and many others. Dr. Crook also writes the "Head Coach" column for Rodale's Prevention magazine. Dr. Crook has served as a consultant to most of the world's major pharmaceutical companies and to governmental agencies ranging from NASA (e.g., your brain, on space) to the FDA. He also has been Chairman of Task Forces formed by both the NIMH and the American Psychological Association (APA) to establish guidelines for the diagnosis and treatment of adult-onset cognitive disorders. Dr. Crook has also been the Principal Investigator on more than 50 large, multi-center studies related to the effects of drugs on cognition and several hundred smaller studies.

Labels: , , ,

This page is powered by Blogger. Isn't yours?